Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Spiro Therapeutics Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the company's formal remarks, we will open the call for questions. Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcements on the Spiro Therapeutics website at www.spirotherapeutics.com. At this time, I would like to turn the call over to Michael Wood, Managing Director at Lifestyle Advisors. Mr. Wood, please go ahead. Thank you, operator, and thank you all for participating in today's conference call. This afternoon, Spiro Therapeutics released financial results and provided a business update for the fourth quarter and full year of 2023. The press release is available on the investors' page of Spira Therapeutics' website. Before I begin, I'd like to remind you that some of the information presented in this conference call contains forward-looking statements based on our current expectations, including statements about the future development and commercialization of Tebepenem HBR, SBR 720, SBR 206, and the design, initiation, timing, progress, and results of the company's pre-trial studies and clinical trials and its research development programs. management's assessment of the results of such preclinical studies and clinical trials, the company's cash forward and anticipated expenses, the sufficiency of the cash resources. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those contained in such statements. Several factors that could cause or contribute to such differences are described in detail in...